Moderna plunges 26% on leaked cancer vaccine trial data
Alpha Vantage · Benzinga · · AI-summarised by FinFlash
Moderna shares fell 26% after leaked Phase 3 data for its cancer vaccine with Merck showed a 42% reduction in recurrence or death, below investor hopes for a miracle cure. Influencer Shane Stoffer flipped bearish hours before the leak, calling the timing a "giant stroke of luck." The stock now trades far above the Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context